Osimertinib treatment after surgery for high-risk stage I lung cancer

Efficacy and Safety of Osimertinib Adjuvant Therapy in High-risk Stage I EGFRm NSCLC After Complete Resection(OSTAR): a Prospective, Single-arm Study

This study is testing if taking Osimertinib after surgery can help people with high-risk stage I lung cancer stay cancer-free longer.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 65 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Tianjin Medical University Cancer Institute and Hospital (other)
• Drugs / interventions: Osimertinib, ocitinib, radiation
• Locations: 1 site (Tianjin, Tianjin Municipality)
• Trial ID: NCT05686434 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy and safety of Osimertinib as an adjuvant therapy in patients with completely resected stage I non-squamous non-small cell lung cancer (NSCLC) who have high-risk factors. Patients will be screened for common EGFR-sensitive mutations and must have undergone complete tumor resection. The treatment involves administering Osimertinib daily for three years, with regular follow-ups to assess disease-free survival and overall survival. The study aims to determine the impact of this therapy on patient outcomes following surgery.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with completely resected stage I non-squamous NSCLC and confirmed EGFR-sensitive mutations.

Not a fit: Patients with non-EGFR-sensitive mutations or those who have not undergone complete tumor resection may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve disease-free survival rates for patients with high-risk stage I NSCLC.

How similar studies have performed: Other studies have shown promising results with EGFR-targeted therapies in NSCLC, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

1. The subject will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;
2. Male and female, ≥18 years old;
3. Primary non-squamous NSCLC confirmed histologically by the central laboratory;
4. Brain imaging examinations should be performed before surgery or enrollment;
5. The patient was clinically confirmed as stage I by imaging, and was staged according to the eighth edition of TNM lung cancer;
6. As confirmed by the central laboratory, the tumor contains one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), alone or in conjunction with other EGFR mutations, including T790M;
7. The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);
8. Central laboratory pathology confirmed solid and/or micropapillary component ≥10%, or STAS;
9. The interval from operation to adjuvant Osimertinib treatment is no more than 10 weeks;
10. WHO physical status score is 0\~1;
11. Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;
12. At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug, or else one of the following criteria must be met at the time of screening to demonstrate the possibility of non-fertility:

    * Postmenopausal was defined as over 50 years of age and amenorrhea for at least 12 months after cessation of all exogenous hormone therapy.
    * Women under 50 should be considered to have stopped menstruating if they have stopped menstruating for 12 months or more after stopping exogenous hormone therapy and their LH and FSH levels are within the agency's postmenopausal range.
13. Irreversible surgical sterilization recorded by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, but not tubal ligation;Male subjects must be willing to use barrier contraception.

Exclusion Criteria:

1. Exposure to other antitumor therapies before enrollment;
2. Patients who only received segmental resection and wedge resection;
3. History of other malignancies, other than non-melanoma skin cancer, carcinoma in situ or other solid tumors that have been effectively treated, and the treating physician has determined that there is no evidence of disease recurrence for 5 years after treatment;
4. Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Omission requirement for screening chronic diseases;
5. Any of the following cardiac criteria:

   * QTc values obtained using screening clinic ECG machines mean resting corrected QT interval (QTc) \> 470 milliseconds from 3 electrocardiogram (ECG) tests,
   * Any abnormalities in rhythm, conduction, or morphology of a clinically significant resting ECG, such as left bundle branch block, third degree heart block, and second degree heart block.
   * Any factors that increase the risk of prolonged QTc or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, sudden unexplained death under 40 years of age in a first-degree relative or any concomitant medication known to prolong the QT interval.
6. Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;
7. Lack of adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count \<1.5×10⁹/L;Platelet count \<100×10⁹/L;Hemoglobin \<90 g/L;Alanine aminotransferase \> 2.5 ULN; Aspartate aminotransferase \>2.5 times ULN;Total bilirubin \> 1.5 ULN;Serum creatinine \>1.5 ULN with creatinine clearance \<50 mL/min \[as measured or calculated by Cockcroft and Gault formulas\] - creatinine clearance only needs to be confirmed when creatinine \>1.5 ULN);
8. History of hypersensitivity to active or inactive excipients of Osimertinib or drugs with similar chemical structures or classes to ocitinib;
9. Uncontrolled nausea and vomiting, chronic gastrointestinal illness, inability to swallow formulated drugs, or prior major bowel resection that prevents adequate absorption of Osimertinib;
10. Any evidence of corneal injury confirmed by ophthalmic examination through slit lamp evaluation;
11. The patient is pregnant or nursing;
12. History of allergy to ocitinib active or inactive excipients or drugs similar in chemical structure or class to Osimertinib;
13. If the patient is unlikely to comply with study procedures, restrictions, and requirements, the investigator judges that the patient should not participate in the study.

Where this trial is running

Tianjin, Tianjin Municipality

• Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality, China (RECRUITING)

Study contacts

• Principal investigator: Dongsheng Yue — Tianjin Medical University Cancer Institute and Hospital
• Study coordinator: chen chen

Conditions: NSCLC, Stage I